Is streptolysin S of group A streptococci a virulence factor?

APMIS

Volumn 107, Issue 12, 1999, Pages 1051-1059

  Ginsburg, Isaac ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Albumin hemolysin hemolysis; Cell bound streptolysin S; Cytotoxicity; Flesheating syndromes; Synergism

Indexed keywords

ALBUMIN; CYTOKINE; HEMOLYSIN; IMMUNOGLOBULIN; MEMBRANE PHOSPHOLIPID; OXIDIZING AGENT; PROTEINASE; REACTIVE OXYGEN METABOLITE; STREPTOLYSIN S; VIRULENCE FACTOR;

BACTERIAL VIRULENCE; CELL DAMAGE; EPITHELIUM CELL; FASCIITIS; HUMAN; MULTIPLE ORGAN FAILURE; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION;

EID: 0033396215     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01509.x     Document Type: Review

References (67)

1. 1. Ginsburg I. Streptococcus. In: Braude AI, Davis CE, Fierer J, editors. Infectious Diseases and Medical Microbiology. Philadelphia: Saunders Company, 1986:242-53.
2. 2. Ayoub EM. The search for host determinants of susceptibility to rheumatic fever: the missing link. Circulation 1984;69:197-201.
3. 3. Stollerman GH. Rheumatogenic streptococci and autoimmunity. Clin Immunol Immunopathol 1991;61:131-42.
4. 4. Abolnik IZ, Sexton DJ. Necrotizing fasciitis and myositis caused by group A streptococci. Epidemiology, diagnosis and treatment of "flesh-eating bacteria". NC Med J 1994;55:464-6.
5. 5. Denny FW Jr. A 45-year perspective on the streptococcus and rheumatic fever: The Edward H. Kass lecture in infectious disease history. Clin Infect Dis 1994;19:1110-2.
6. 6. Schlievert PM, Assimacopoulos AP, Cleary PP. Severe invasive group A streptococcal disease: clinical description and mechanisms of pathogenesis. J Lab Clin Med 1996;127:12-22.
7. 7. Krause R. Microbial factors in disease emergence illustrated by streptococcal toxic shock syndrome. FEMS Immunol Microbiol 1997;18: 227-32.
8. 8. Giuliano ED, Lewis F, Hadley K. Bacteriology of necrotizing fasciitis. Am J Surg 1997;134:52-6.
9. 9. Stollerman GH. Changing streptococci and prospects for the global eradication of rheumatic fever. Perspect Biol Med 1997;40:165-89.
10. 10. Ferrieri P, Horaud T. Unraveling the mysteries of streptococci and their relations with the host. Trends Microbiol 1997;5:5-7.
11. 11. Pichichero ME. Group A beta hemolytic streptococcal infections. Pediatr Rev 1998;19:291-302.
12. 12. Carapetis JR, Currie BJ, Kaplan EL. Epidemiology and prevention of group A streptococcal infections: acute respiratory tract infections, skin infections, and their sequelae at the close of the twentieth century. Clin Infect Dis 1999;28:205-10.
13. 13. Horn DL, Zabriskie JB, Austrian R, Patrick Cleary, Ferreti JJ, Fischetti VA, et al. Why have group A streptococci remained susceptible to penicillin? Report of a symposium. Clin Infect Dis 1998;26:1341-5.
14. 14. Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1990;2:285-314.
15. 15. Cleary P, Retnoningrum D. Group A streptococcal immunoglobulin-binding proteins: adhesins, molecular mimicry or sensory proteins? Trends Microbiol 1994;2:131-6.
16. 16. Ginsburg I. Mechanisms of cell and tissue injury induced by group A streptococci: relation to post-streptococcal sequelae. J Infect Dis 1972; 126:294-340, 419-56.
17. 17. Ginsburg I. Can hemolytic streptococci be considered "forefathers" of modern phagocytes? Both cell types freely migrate in tissue and destroy host cells by a "synergistic cross-talk" among their secreted agonists. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1994; 109:147-58.
18. 18. Ginsburg I. Streptolysin S. In: Montie TC, Kadas S, Ajl SJ, editors. Microbial toxins. New York, NY: Academic Press, 1972: 99-171.
19. 19. Alouf JE. Streptococcal toxins (streptolysin O, streptolysin S, erythrogenic toxin). Pharmacol Ther 1980; 11:661-717.
20. 20. Ginsburg I, Kohen R. Cell damage in inflammatory and infectious sites might involve a coordinated "cross-talk" among oxidants, microbial haemolysins, and ampiphiles, cationic proteins, phospholipases, fatty acids, proteinases and cytokines. Free Rad Res 1995;22:489-517.
21. 21. Ginsburg I. Could synergistic interactions among reactive oxygen species, proteinases, membrane-perforating enzymes, hydrolases, microbial hemolysins, and cytokines be the main cause of tissue damage in infectious and inflammatory conditions? Med Hypotheses 1998; 51:337-46.
22. 22. Ginsburg I, Ward PA, Varani J. Can we learn from the pathogenetic strategies of group A hemolytic streptococci how tissues are injured and organs fail in post-infectious and inflammatory sequelae? FEMS Immunol Med Microbiol 1999; 25:325-38.
23. 23. Todd EW. The differentiation of two distinct serological varieties of streptolysins. Streptolysin O and streptolysin S. J Pathol Bacteriol 1938;47: 423-45.
24. 24. Weld JT. The toxic properties of serum extracts of hemolytic streptococci. J Exp Med 1934;59: 83-95.
25. 25. Ginsburg I, Harris TN. Oxygen-stable hemolysins of group A streptococci. II. Chromatographic and electrophoretic studies. J Exp Med 1963;118: 919-34.
26. 26. Ginsburg I, Bentwich Z, Harris TN. Oxygen-stable hemolysins of group A streptococci. III. The relation of the cell-bound hemolysin to Streptolysin S. J Exp Med 1965;121:633-46.
27. 27. Ginsburg I, Harris TN. Oxygen-stable hemolysins of group A streptococci. IV. Studies on the mechanism of lysis by cell-bound hemolysin of red blood cells and Ehrlich ascites tumor cells. J Exp Med 1965;121:747-56.
28. 28. Calandra GB, Cole RM. Membrane and cytoplasmic location of streptolysin S precursor. Infect Immun 1981;31:386-90.
29. 29. Theodore TS, Calandra GB. Streptolysin S activation by lipoteichoic acid. Infect Immun 1981; 33:326-8.
30. 30. Koyama J, Egami F. Biochemical studies on streptolysin S formed in the presence of yeast ribonucleic acid. I. The purification and some properties of the toxin. J Biochem (Japan) 1963; 53:147-54.
31. 31. Taketo A, Yaketo Y. Enhanced production of cell-bound and extra cellular streptolysin S by hemolytic streptococci treated with proteases. Z Naturforsch 1958;40:166-9.
32. 32. Akao T, Takahashi T, Kobayshi H. Purification and characterization of a peptide essential formation of streptolysin S by Streptococcus pyogenes. Infect Immun 1992;60:4777-80.
33. 33. Marcus Z, Davies AM, Ginsburg I. Oxygen-stable hemolysins of group A streptococci. V. Effect on rat heart and kidney cells grown in tissue culture. Exp Mol Pathol 1966;5:93-107.
34. 34. Lai CY, Wang MT, de Faria JB, Akao T. Streptolysin S: improved purification and characterization. Arch Biochem Biophys 1978;191:804-12.
35. 35. Loridan C, Alouf JE. Purification of RNA-core induced streptolysin S, and isolation and hemolytic characteristics of the carrier-free toxin. J Gen Microbiol 1986;132:307-15.
36. 36. Alouf JE, Loridann C. Production, purification, and assay of streptolysin S. Methods Enzymol 1988;165:59-64.
37. 37. Okazaki H. Streptolysin S' of Streptococcus pyogenes: studies on phospholipase activity. J Biochem (Tokyo) 1971;70:867-8.
38. 38. Bernheimer AW. Hemolysins of streptococci. Characterization and effect on biological membranes. In: Wannamaker LW, Matson JM, editors. Streptococci and streptococcal diseases. New York: Academic Press, 1972;19-31.
39. 39. Duncan JL, Mason L. Characteristics of streptolysin S hemolysis. Infect Immun 1976;14:77-82.
40. 40. Bernheimer AW, Rudy B. Interaction between membranes and cytolyic peptides. Biochem Biophys Acta 1986;864:123-41.
41. 41. Buckingham L, Duncan JL. Approximate dimensions of membrane lesions produced by streptolysin S and streptolysin O. Biochem Biophys Acta 1983;729:115-22.
42. 42. Zeiri N, Bentwich Z, Boss JH, Ginsburg I, Harris TN. Organ lesions produced in rabbits by group A streptococci and some of their extracellular products. Am J Pathol 1967;51:351-71.
43. 43. Jakeman KJ, Smith H, Sweet C. Influenza virus enhancement of membrane leakiness induced by staphylococcal alpha toxin, diphtheria toxin and streptolysin S. J Gen Virol 1991;72:111-5.
44. 44. Hryniewicz W, Roszkowski W, Rykiel B, Kanclerski K, Jeljaszewicz J. Effect of streptolysin S from Streptococcus pyogenes on contact sensitivity in mice. Zentralbl Bakteriol Mikrobiol Hyg [A] 1986;262:454-60.
45. 45. Raya SA, Trembovler V, Shohami E, Lazarovici P. Cytolysins increase intracellular calcium and induce eicosanoids release by pheochromocytoma PC12 cell culture. Nat Toxins 1993;1:263-70.
46. 46. Griffiths BB, Rhee H. Effects of hemolysins of groups A and B streptococci on cardiovascular system. Microbios 1992;69:17-27.
47. 47. Duncan JL, Buckingham L. Effect of streptolysin S on liposomes. Influence of membrane lipid on toxin action. Biochem Biophys Acta 1961; 20:6-12.
48. 48. Ginsburg I. Action of streptococcal hemolysins and proteolytic enzymes on Ehrlich ascites tumor cells. Br J Exp Pathol 1959;40:417-27.
49. 49. Betschel SD, Borgia SM, Barg NL, Low DE, De Azavedo JCS. Reduced virulence of group A streptococcal Tn916 mutants that do not produce streptolysin S. Infect Immun 1998;66:1671-9.
50. 50. Lukomski S, Burns EH Jr, Wyde PR, Podbielski A, Rurangirwa J, Moore-Poveda DK, Musser JM. Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs. Infect Immun 1998;66:771-6.
51. 51. Lukomski S, Montgomery CA, Rurangirwa J, Geske RS, Barrish JP, Adams GJ, et al. Extracellular cysteine protease produced by Streptococcus pyogenes participates in the pathogenesis of invasive skin infection and dissemination in mice. Infect Immun 1999;67: 1779-88.
52. 52. Shanley TP, Schrier D, Kapur V, Kehoe M, Musser JM, Ward P. Streptococcal cysteine protease augments lung injury induced by products of group A streptococci. Infect Immun 1996;64: 870-7.
53. 53. Ginsburg I, Gibbs DF, Schuger L, Johnson KJ, Ryan US, Ward PA, et al. Vascular endothelial cell killing by combinations of membrane-active agents and hydrogen peroxide. Free Radic Biol Med 1989;7:369-76.
54. 54. Varani J, Ginsburg I, Schuger I, Gibbs DF, Bromberg J, Johnson KJ, et al. Endothelial cell killing by neutrophils. Synergistic interaction of oxygen products and proteases. Am J Pathol 1989;125:435-8.
55. 54. Ginsburg I, Misgav R, Pinson A, Varani J, Ward PA, Kohen R. Synergism among oxidants, proteinases, phospholipases, microbial hemolysins, cationic proteins, and cytokines. Inflammation 1992;16:519-38.
56. 55. Ginsburg I, Varani J. Interaction of viable streptococci and hydrogen peroxide in killing of vascular endothelial cells. Free Radic Biol Med 1993;14:495-500.
57. 56. Ginsburg I, Mitra RS, Gibbs DF, Varani J, Kohen R. Killing of endothelial cells and release of arachidonic acid. Synergistic effects among hydrogen peroxide, membrane-damaging agents, cationic substances, and proteinases and their modulation by inhibitors. Inflammation 1993; 17:295-319.
58. 57. Ginsburg I, Kohen R. Synergistic effects among oxidants, membrane-damaging agents, fatty acids, proteinases, and xenobiotics: killing of epithelial cells and release of arachidonic acid. Inflammation 1995;19:101-18.
59. 2 inhibitor, tetracycline and antioxidants protect epithelial cells against damage induced by synergism among streptococcal hemolysins, oxidants, and proteinases: relation to the prevention of post-streptococcal sequelae and septic shock. FEMS Immunol Med Microbiol 1998;22:247-56.
60. 59. Ofek I, Rabinowitz-Bergner S, Ginsburg I. Oxygen-stable hemolysins of group A streptococci. VIII. Leukotoxic and antiphagocytic effects of streptolysins S and O. Infect Immun 1972;6:459-64.
61. 60. Ginsburg I, Yedgar S, Varani J. Diethyldithiocarbamate and nitric oxide synergize with oxidants and with membrane-damaging agents to injure mammalian cells. Free Radic Res 1997;27:143-64.
62. 2: a novel mechanism for cell damage in inflammatory processes. FEBS Lett 1996;383: 75-8.
63. 62. Ofek I, Zafriri D, Goldhar J, Eisenstein BI. Inability of toxin inhibitors to neutralize enhanced toxicity caused by bacteria adherent to tissue culture cells. Infect Immun 1990;58:3737-42.
64. 63. Elliott SD, Dole VP. An inactive precursor of streptococcal proteinase. J Exp Med 1947;85: 305-20.
65. 64. Ginsburg I. Action of phospholipids on the cytotoxic effects of rabbit antibodies against Ehrlich ascites tumor cells. Br J Exp Pathol 1960;41:648-59.
66. 65. Stevens DL. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome. Clin Infect Dis 1998;26: 639-41.
67. 66. Gibson RL, Nizer V, Rubin CE. Group B streptococcal-hemolysin promotes injury of lung microvascular endothelial cells. Pediatr Res 1999; 45:626-34.